文献速递脑血管病

达比加群逆转后卒中再灌注治疗:全国队列研究

Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort.
PubMed 文献 · Neurology · 2020-02-20

依达赛珠单抗使用率从2017年1.3%升至2018年6%,虽门-针时间延长22分钟,但症状性颅内出血和7天死亡率与未暴露患者相似。

要点

  • 2018年溶栓患者中6%使用依达赛珠单抗,较2017年1.3%显著增加。
  • 依达赛珠单抗组门-针时间延长22分钟(83 vs 61分钟,p=0.0006)。
  • 症状性颅内出血和7天死亡率与未暴露患者无显著差异。

核心结论

  • 依达赛珠单抗可用于正在服用达比加群的卒中患者以促进溶栓,其安全性和早期临床结局与常规管理患者相似。

主要发现

  • 同期386例取栓患者中8例(2.1%)首先接受依达赛珠单抗治疗。
  • 依达赛珠单抗组门-针时间83分钟(54-110)vs 61分钟(43-85),p=0.0006。
  • 症状性颅内出血在依达赛珠单抗组2例(3.9%),其他溶栓患者49例(3.8%),p=0.97。
  • 7天死亡:依达赛珠单抗组3例(5.9%),其他溶栓患者101例(7.9%),p=0.61;依达赛珠单抗组无显著血栓并发症。

临床怎么用

  • 对正在服用达比加群的急性缺血性卒中患者,可考虑使用依达赛珠单抗后行静脉溶栓。
  • 使用依达赛珠单抗可能导致门-针时间延长约22分钟,需优化流程。

局限性

  • 本研究为观察性队列研究,证据等级为Class III。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the frequency and utilization trends of dabigatran reversal with idarucizumab and compare associated complications, outcomes, and door-to-needle times to those of patients not exposed to idarucizumab in a nationwide cohort of thrombolyzed patients over a 24-month period. METHODS: This is an observational cohort study of all New Zealand patients with stroke treated with stroke reperfusion entered into a mandatory online national registry. Each hospital records data including patient demographics, treatment delays, complications, 7-day outcomes, and idarucizumab use. RESULTS: Between 1 January 2017 and 31 December 2018, 1,336 patients received thrombolysis. Fifty-one patients received idarucizumab prior to thrombolysis (median [interquartile range] age 73 [57-83] years): 8 (1.3%) in 2017 and 43 (6%) in 2018 (p < 0.001). Over the same 24-month period, 386 patients had stroke clot retrieval, of whom 8 (2.1%) were first treated with idarucizumab. Idarucizumab-treated patients had slower door-to-needle times (83 [54-110] minutes vs 61 [43-85] minutes, p = 0.0006). Symptomatic intracerebral hemorrhage occurred in 2 (3.9%) of the idarucizumab-treated patients and 49 (3.8%) of the other thrombolyzed patients (p = 0.97). None of the idarucizumab-treated patients had significant thrombotic complications. At 7 days, 3 (5.9%) idarucizumab-treated and 101 (7.9%) of the other thrombolyzed patients had died (p = 0.61). CONCLUSION: Idarucizumab was used in 6% of all thrombolyzed patients in a national cohort during 2018, up from 1.3% in 2017. Idarucizumab appeared to be safe with similar clinical outcomes to routinely managed patients, despite a 22-minute door-to-needle time delay. Idarucizumab can facilitate thrombolysis in patients with stroke taking dabigatran. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that idarucizumab use is associated with similar early post-thrombolysis outcomes compared with patients not exposed to this drug.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Barber PA, Wu TY, Ranta A, et al. Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort. Neurology. 2020. PMID: 32079737. doi:10.1212/WNL.0000000000009155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。